Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 277-283 , June 2006

Actual usage and clinical effectiveness of insulin preparations in patients with Type 1 diabetes mellitus in Japan: CoDiC®-based analysis of clinical data obtained at multiple institutions (JDDM 3)

  • Azuma Kanatsuka

      Affiliations

    • Diabetes Center, Chiba Central Medical Center, 1835-1 Kasori, Wakaba-ku, Chiba 264-0017, Japan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Koichi Kawai

      Affiliations

    • Kawai Clinic, Tsukuba, Japan
    • ,
  • Koichi Hirao

      Affiliations

    • H.E.C. Science Clinic, Yokohama, Japan
    • ,
  • Mariko Oishi

      Affiliations

    • Oishi Internal Medicine Clinic, Kyoto, Japan
    • ,
  • Hirofumi Takagi

      Affiliations

    • School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
    • ,
  • Masashi Kobayashi

      Affiliations

    • The First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan
    • ,
  • Japan Diabetes Clinical Data Management Study Group

Received 5 November 2004 ,Revised 15 February 2005 ,Accepted 29 March 2005.

References 

  1. The Expert Committee on the Diagnosis, Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet. Care. 1997;20:1183–1197
  2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998;15:539–553
  3. Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee of Japan Diabetes Society on the Classification and Diagnosis of Diabetes Mellitus. Japan Diab. Soc. 1999;42:395–404(in Japanese)
  4. Lindholm A, McEwen J, Riis AP. Improved post-prandial glycemoc control with insulin aspart. Diabet. Care. 1999;22:801–805
  5. Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith GD. Role of C-terminal β-chain residues in insulin assembly: the structure of hexameric LysB28 ProB29 human insulin. Structure. 1995;3:615–622
  6. Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabet. Care. 2002;25:883–888
  7. Kobayashi M, Yamazaki K, Hayashi R. Diabetes campaign in Toyama prefecture and development of computerized diabetes care. Int. Diabet. Monitor. 1999;34–37
  8. M. Kobayashi, K. Yamazaki, K. Hirao, M. Oishi, K. Kanatsuka, M. Yamauchi, et al., The status of diabetes control and anti-diabetic drug therapy in Japan – Across-sectional survey of 17,000 patients with diabetes mellitus (JDDM1), Diabet. Res. Clin. Pract., in press.
  9. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare, June 30, 2003.
  10. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet. Med. 1994;11:299–303
  11. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (Type 1) diabetes mellitus. Ann. New York Acad. Sci. 2002;958:117–130
  12. Pieber TR, Brunner GA, Schnedl WJ, Schattenberg S, Kaufmannn P, Krejes GJ. Evaluation of a structured outpatient group education program for intensive insulin therapy. Diabet. Care. 1995;18:625–630
  13. Berger M, Muhlhauser I. Implementation of intensified insulin therapy: a European perspective. Diabet. Med. 1995;12:201–208
  14. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396–402
  15. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia. 1994;37:713–720
  16. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AAR, et al. Prandial glycemia after carbohydrate-rich meal in Type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet. Med. 1996;13:625–629
  17. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs. Humulin R insulin treatment in young subjects with Type 1 diabetes. Diabet. Med. 1996;13:47–52
  18. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. The Multicenter Insulin Lispro Study Group Reduction of postprandial hyperglycemia and frquency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes. 1997;46:265–270
  19. HollemanF , Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH The Benelux-UK Insulin Lispro Study Group. Reduce frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabet. Care. 1997;20:1827–1832
  20. Ahmed ABE, Home PD. The effect of insulin analog lispro on night time blood glucose control in Type 1 diabetic patients. Diabet. Care. 1998;21:32–37
  21. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall M-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia. 2004;47:622–629
  22. Kwolewski AS, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type 1 diabetes mellitus and impaired glucose tolerance in adults. N. Engl. J. Med. 1987;317:1390–1398
  23. Gorus FK Belgian Diabetes Registry. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Diabet. Metab. Rev. 1997;4:247–274
  24. Pipeleers D, Ling Z. Pancreatic β-cells in insulin-dependent diabetes. Diabet. Metab. Rev. 1992;8:209–227
  25. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y The Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N. Engl. J. Med. 2000;342:301–307
  26. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, et al. Fulminant type 1 diabetes. Diabet. Care. 2003;26:2345–2352
  27. The Diabetes Control and Complications Trial Research Group . The absence of glycemic threshhold for the development of long-term complications. Diabetes. 1996;45:1289–1298
  28. Pickup J, Mattock M, Kerry S. Glycemic control with continuous subcutaneous insulin infusion compared with intensive insulin injection in patients with type 1 diabetes: meta-analysis of randomized, controlled trials. BMJ. 2002;324:705

☆ A part of the manuscript has been presented at the Annual Meeting of the Japan Diabetes Society, 22–24 May 2003, Toyama, Japan: A. Kanatsuka, M. Kobayashi, H. Takagi, Actual Using Status of Insulin Preparations and Oral Hypoglycemic Agents —CoDiC-based Analysis of Clinical Data Obtained at Multiple Institutions, Journal of the Japan Diabetes Society 46 Supplement 1, 2003 (in Japanese) and at the 18th Congress of the Internal Diabetes Federation, 24–29 August 2003, Paris, France: A. Kanatsuka, M. Kobayashi, H. Takagi, Actual Using Status of Insulin Preparations and Oral Hypoglycemic Agents in Japan —CoDiC-based Analysis of Clinical Data Obtained at Multiple Institutions, Diabetologia 46 Supplement 2, 2003.

PII: S0168-8227(06)00035-0

doi: 10.1016/j.diabres.2005.03.040

Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 277-283 , June 2006

Article Tools

* Image Usage & Resolution